Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling
By Denny Jacob
Liquidia's new drug application for yutrepia is cleared for potential approval from the U.S. Food and Drug Administration following a court ruling in a lawsuit filed by United Therapeutics.
Judge Andrews of U.S. District Court for the District of Delaware set aside the injunction issued in August 2022 in the lawsuit filed by United Therapeutics. As a result, the FDA is no longer enjoined from issuing final approval of the new drug application for yutrepia.
The FDA tentatively approved yutrepia to treat pulmonary arterial hypertension in November 2021. Liquidia in July amended its application to add the indication treat pulmonary hypertension associated with interstitial lung disease.
United Therapeutics filed a notice of appeal with respect to Judge Andrews' decision to set aside the injunction. It also filed two separate lawsuits in which it's seeking to obtain new injunctions to prevent launch of yutrepia for the treatment of pulmonary hypertension associated with interstitial lung disease.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 01, 2024 06:37 ET (10:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations